Clear-cell adenocarcinoma

Types

Cervical

Cervical adenocarcinoma is less likely to be caused by high-risk HPV strains than cervical squamous cell carcinoma is: around 10-15% of cervical adenocarcinomas are non-HPV-related. Cervical clear cell carcinoma (CCC) is typically HPV-negative, though many are p16 positive. Traditionally, clear cell carcinoma of the lower genital tract in females was related to diethylstilbestrol (DES) exposure in utero. More recently, these cases develop sporadically or are related to vaginal adenosis. Risk factors are similar to other types of cervical cancer, including immunosuppression, smoking, long-term oral contraceptive use, increased number of sexual partners, early onset of sexual activity, hormone replacement therapy, and obesity.

As with other types of cervical cancer, cervical CCC is diagnosed with a cervical biopsy. Further treatment is managed similarly to other types of cervical cancer, such as performing an excision procedure in the form of a cold knife conization or a loop electrosurgical excision procedure (LEEP). Further surgical management depends upon the depth of tumor invasion. Invasive tumors may require chemotherapy and radiation treatment. Cervical CCC appears to have a similar prognosis to other types of cervical cancer.

Ovarian

Main article: ovarian clear-cell carcinoma

Ovarian clear cell carcinoma is a subtype of epithelial ovarian carcinoma. These tumors are typically unilateral. They are associated with endometriosis, in which endometrial tissue grows outside the uterine cavity. Benign endometriotic cysts, also known as adenofibromas, are frequently the source of these tumor cells.

Treatment of ovarian clear cell carcinoma typically begins with surgery to remove the ovaries and other affected organs. Chemotherapeutic treatment of gynecological cancers typically includes a platinum-based therapy and a taxane. Clear cell ovarian tumors have a higher rate of resistance to these medications. Other treatment routes, including immunologic agents against certain biomarkers, are being explored.

Uterine

Main article: uterine clear-cell carcinoma

Uterine clear cell carcinoma is a rare, aggressive form of endometrial cancer. This is an example of a Type II endometrial carcinoma, meaning that it is unrelated to endometrial hyperplasia. Uterine clear cell tumors arise from an endometrium that has become thin and dry. Patients usually present with abnormal uterine bleeding.

Treatment of uterine clear cell carcinoma is primarily surgical. A tumor debulking procedure is typically performed, consisting of a total hysterectomy and bilateral salpingo-oopherectomy. Depending on the level of tumor invasion, an omentectomy and other malignancy removal may be performed at the same time. Cytoreductive surgery, which involves removing all visible cancer cells during the operation, is the current standard of care. Minimally invasive surgical techniques are preferred over open surgeries, as patients tend to have better short-term outcomes after the surgery.

Patients may be treated with chemotherapy or radiation following tumor debulking. Platinum-based chemotherapy is the mainstay for most gynecologic cancers, including endometrial cancers. Depending on the genomic subtype of the tumor, various other chemotherapeutic or immunologic therapies may be employed.

Vaginal

Main article: clear-cell adenocarcinoma of the vagina

Clear cell adenocarcinoma of the vagina is a rare cancer that is related to DES exposure in utero. DES was a drug previously given to some women with high-risk pregnancies to prevent miscarriage. Women who were exposed to DES in utero should be evaluated yearly with a pap smear and pelvic exam due to risk of developing clear cell adenocarcinoma.

Vaginal clear cell carcinoma frequently presents with abnormal uterine bleeding. As with other gynecological cancers, treatment varies with the stage of the cancer. Lower grade tumors can be treated with surgical resection, while higher grade tumors may need chemotherapy and radiation.

References

References

1. (2 February 2011). "NCI Dictionary of Cancer Terms".
2. (2022). "Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis". Frontiers in Endocrinology.
3. (November 2019). "Recent advances in invasive adenocarcinoma of the cervix". Virchows Archiv.
4. (January 2020). "Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification". Histopathology.
5. (June 2000). "Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy". Cancer.
6. (June 2008). "Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers". Gynecologic Oncology.
7. (2008). "Innovative Endocrinology of Cancer". Springer New York.
8. (March 2022). "Clear cell carcinoma of the endometrium". Gynecologic Oncology.
9. (June 2012). "Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine.
10. Tournaire, Michel. (23 December 2020). "Screening for cancers of the cervix and vagina for women exposed to diethylstilbestrol (DES) in utero". Journal of Gynecology Obstetrics and Human Reproduction.
11. "Clear cell carcinoma-vagina".